Artal Group S.A. Viking Therapeutics, Inc. Transaction History

Artal Group S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$17.4 - $94.5 $4.42 Million - $24 Million	253,863 New	253,863 $20.8 Million
Q1 2023 May 12, 2023	BUY	$8.08 - $17.33 $2.42 Million - $5.2 Million	300,000 New	300,000 $5 Million
Q1 2020 May 14, 2020	SELL	$3.45 - $7.95 $1.21 Million - $2.78 Million	-350,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$6.55 - $8.6 $1.64 Million - $2.15 Million	250,000 Added 250.0%	350,000 $2.41 Million
Q2 2019 Aug 09, 2019	BUY	$7.67 - $10.63 $767,000 - $1.06 Million	100,000 New	100,000 $830,000

442

63.3M

6.23M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.83B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.